Department of Gastroenterology and Pancreatology, ENETS Centre of Excellence, Beaujon Hospital, APHP, Clichy, France; Université de Paris, Paris, France; INSERM U1149, Beaujon Hospital, Clichy, France.
Department of Nuclear Medicine, ENETS Centre of Excellence, Beaujon Hospital, APHP, Clichy, France.
Dig Liver Dis. 2019 Dec;51(12):1720-1724. doi: 10.1016/j.dld.2019.06.022. Epub 2019 Jul 23.
Ki67 proliferation index and tumor uptake on 18fluorodeoxyglucose positron-emitting tomography (FDG-PET) could be correlated in pancreatic neuroendocrine tumors (PanNET), but the evaluation of the former is subject to tumor heterogeneity.
Explore the correlation between Ki67 and FDG-PET uptake at the lesion scale in PanNET.
We identified target lesions ≥10 mm in patients operated on for a PanNET and/or associated metastases with preoperative FDG-PET and without neoadjuvant treatment. We assessed the lesion-by-lesion correlation between Ki67 and the tumor-to-liver SUVmax ratio (SUVmax T/L), and between pathological grade (G) and metabolic grade (mG) (mG1, SUVmax T/L ≤ 1, mG2, SUVmax T/L 1-2.3 and mG3, SUVmax T/L > 2.3).
Twenty-one patients underwent pancreatic (n = 12), liver (n = 2) or combined surgery (n = 7). Overall, 36 target lesions (21 primary PanNET, 13 liver metastases and 2 lymph-node metastases) were identified, of median Ki67 4%. Ki67 correlated with SUVmax T/L (r = 0.55, p < 0.001). Median SUVmax T/L was 0.76, 1.41 and 2.67 for lesions G1, G2 and G3, respectively (p = 0.005). Median Ki67 was 1, 4 and 25 for lesions mG1, mG2 and mG3, respectively (p = 0.005).
Uptake on FDG-PET could predict the pathological grade of PanNET lesions. Hence, FDG-PET could supplement pathological evaluation of tumor biological aggressiveness and could guide the choice of the most relevant lesions to biopsy.
Ki67 增殖指数和 18 氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)在胰腺神经内分泌肿瘤(PanNET)中可能相关,但前者的评估受到肿瘤异质性的影响。
探讨 PanNET 病变水平 Ki67 与 FDG-PET 摄取之间的相关性。
我们确定了在接受胰腺(n=12)、肝脏(n=2)或联合手术(n=7)治疗的 PanNET 患者中,术前 FDG-PET 显示直径≥10mm 的靶病灶,且无新辅助治疗。我们评估了 Ki67 与肿瘤肝脏 SUVmax 比值(SUVmax T/L)之间,以及病理分级(G)和代谢分级(mG)(mG1,SUVmax T/L≤1;mG2,SUVmax T/L 1-2.3;mG3,SUVmax T/L>2.3)之间的病变内相关性。
21 名患者接受了胰腺(n=12)、肝脏(n=2)或联合手术(n=7)。总体而言,共确定了 36 个靶病灶(21 个原发 PanNET、13 个肝转移和 2 个淋巴结转移),Ki67 中位数为 4%。Ki67 与 SUVmax T/L 相关(r=0.55,p<0.001)。G1、G2 和 G3 病灶的 SUVmax T/L 中位数分别为 0.76、1.41 和 2.67(p=0.005)。mG1、mG2 和 mG3 病灶的 Ki67 中位数分别为 1、4 和 25(p=0.005)。
FDG-PET 摄取可以预测 PanNET 病灶的病理分级。因此,FDG-PET 可以补充肿瘤生物学侵袭性的病理评估,并指导选择最相关的病灶进行活检。